200 related articles for article (PubMed ID: 10856095)
1. Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
Patnaik A; MacKinnon J; Goss P; Nagy T; Stewart K; Keating A; Crump M
J Clin Oncol; 2000 Jun; 18(12):2363-8. PubMed ID: 10856095
[TBL] [Abstract][Full Text] [Related]
2. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
3. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
[TBL] [Abstract][Full Text] [Related]
4. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
7. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
Sparano JA; Robert N; Silverman P; Lazarus H; Malik U; Venkatraj U; Sarta C
J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
Ford C; Spitzer G; Reilly W; Adkins D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-81-S17-86. PubMed ID: 9374101
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
Fennelly D; Schneider J; Spriggs D; Bengala C; Hakes T; Reich L; Barakat R; Curtin J; Moore MA; Hoskins W
J Clin Oncol; 1995 May; 13(5):1160-6. PubMed ID: 7537799
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract][Full Text] [Related]
13. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
[TBL] [Abstract][Full Text] [Related]
14. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
[TBL] [Abstract][Full Text] [Related]
17. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
Bezwoda WR; Seymour L; Dansey RD
J Clin Oncol; 1995 Oct; 13(10):2483-9. PubMed ID: 7595697
[TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
[TBL] [Abstract][Full Text] [Related]
20. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]